TY - JOUR
T1 - Advanced pulmonary and cardiac support of COVID-19 Patients
T2 - Emerging recommendations from ASAIO - A "living working document"
AU - Rajagopal, Keshava
AU - Keller, Steven P.
AU - Akkanti, Bindu
AU - Bime, Christian
AU - Loyalka, Pranav
AU - Cheema, Faisal H.
AU - Zwischenberger, Joseph B.
AU - El Banayosy, Aly
AU - Pappalardo, Federico
AU - Slaughter, Mark S.
AU - Slepian, Marvin J.
N1 - Funding Information:
Disclosure: Dr Slepian has research grants from Abiomed and NIH/ NIBIB. Dr Keller has research grant from Abiomed and NIH. Dr Bime has a research grant from NIH/NHLBI. Dr Zwischenberger has research grants from Avalon-Maquet and NIH and is an unpaid consultant for Cytosorbents; Dr El-Banayosy has a research grant from Abbott. The other authors have no conflicts of interest to report.
Publisher Copyright:
© 2020 Lippincott Williams and Wilkins. All rights reserved.
PY - 2020/6/1
Y1 - 2020/6/1
N2 - The severe acute respiratory syndrome (SARS)-CoV-2 is an emerging viral pathogen responsible for the global coronavirus disease 2019 (COVID)-19 pandemic resulting in significant human morbidity and mortality. Based on preliminary clinical reports, hypoxic respiratory failure complicated by acute respiratory distress syndrome is the leading cause of death. Further, septic shock, late-onset cardiac dysfunction, and multiorgan system failure are also described as contributors to overall mortality. Although extracorporeal membrane oxygenation and other modalities of mechanical cardiopulmonary support are increasingly being utilized in the treatment of respiratory and circulatory failure refractory to conventional management, their role and efficacy as support modalities in the present pandemic are unclear. We review the rapidly changing epidemiology, pathophysiology, emerging therapy, and clinical outcomes of COVID-19; and based on these data and previous experience with artificial cardiopulmonary support strategies, particularly in the setting of infectious diseases, provide consensus recommendations from ASAIO. Of note, this is a "living document," which will be updated periodically, as additional information and understanding emerges.
AB - The severe acute respiratory syndrome (SARS)-CoV-2 is an emerging viral pathogen responsible for the global coronavirus disease 2019 (COVID)-19 pandemic resulting in significant human morbidity and mortality. Based on preliminary clinical reports, hypoxic respiratory failure complicated by acute respiratory distress syndrome is the leading cause of death. Further, septic shock, late-onset cardiac dysfunction, and multiorgan system failure are also described as contributors to overall mortality. Although extracorporeal membrane oxygenation and other modalities of mechanical cardiopulmonary support are increasingly being utilized in the treatment of respiratory and circulatory failure refractory to conventional management, their role and efficacy as support modalities in the present pandemic are unclear. We review the rapidly changing epidemiology, pathophysiology, emerging therapy, and clinical outcomes of COVID-19; and based on these data and previous experience with artificial cardiopulmonary support strategies, particularly in the setting of infectious diseases, provide consensus recommendations from ASAIO. Of note, this is a "living document," which will be updated periodically, as additional information and understanding emerges.
KW - ARDS
KW - COVID-19
KW - coronavirus
KW - extracorporeal membrane oxygenation
KW - mechanical circulatory support
KW - mechanical ventilation
UR - http://www.scopus.com/inward/record.url?scp=85085885105&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85085885105&partnerID=8YFLogxK
U2 - 10.1097/MAT.0000000000001180
DO - 10.1097/MAT.0000000000001180
M3 - Article
C2 - 32358232
AN - SCOPUS:85085885105
SN - 1058-2916
VL - 66
SP - 588
EP - 598
JO - ASAIO Journal
JF - ASAIO Journal
IS - 6
ER -